Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial-Reference-Cited by-同舟云学术

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

Published:2015-11-14 Issue:3 Volume:154 Page:509-520
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Cortes Javier,Hudgens Stacie,Twelves Chris,Perez Edith A.,Awada Ahmad,Yelle Louise,McCutcheon Susan,Kaufman Peter A.,Forsythe Anna,Velikova Galina

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-015-3633-7.pdf

Reference36 articles.

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205

2. Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C, Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO) (2012) Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol 138:221–229. doi: 10.1007/s00432-011-1091-0

3. Park IH, Lee KS, Ro J (2015) Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer 15:e55–e62. doi: 10.1016/j.clbc.2014.09.001

4. Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8:224–233. doi: 10.3816/CBC.2008.n.025

5. Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915. doi: 10.1200/JCO.2014.57.9334

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study;Future Oncology;2024-09-12

2. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial;eClinicalMedicine;2024-08

3. Eribulin in breast cancer: Current insights and therapeutic perspectives;World Journal of Experimental Medicine;2024-06-20

4. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany;Cost Effectiveness and Resource Allocation;2024-03-08

5. Statistical analysis plan for the PRO B study: open-label, superiority randomised controlled trial of alarm-based patient-reported outcome monitoring in patients with metastatic breast cancer;Trials;2024-03-07